Takeda Acquires US Biologics Manufacturing Facility

Published on: January 6, 2016

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

Takeda Pharmaceutical Company Limited announced the acquisition of a Brooklyn Park, Minnesota-based biologics manufacturing facility from Baxalta Inc in a Jan. 6, 2016 press announcement.

Takeda is a Japan-based pharmaceutical company focused on research and development. It is the largest pharmaceutical company in Japan.

According to the company, Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. FDA approved Entyvio in May 2014 for the treatment of ulcerative colitis and moderate-to-severe Crohn’s disease.

Terms of the transaction were not disclosed.

Source: Takeda Pharmaceutical Company